Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma.

Bai B, Vodák D, Nakken S, Wise JF, Blaker YN, Lingjærde OC, Brodtkorb M, Hilden V, Trøen G, Lorenz S, Lawrence MS, Myklebost O, Meza-Zepeda L, Beiske K, Hovig E, Smeland EB, Holte H, Myklebust JH.

Blood. 2019 Nov 13;134(Supplement_1):20. doi: 10.1182/blood-2019-128403.

PMID:
31723999
2.

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S.

Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678.

3.

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7. No abstract available.

4.

Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response.

Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM.

Cytometry A. 2019 Apr;95(4):442-449. doi: 10.1002/cyto.a.23737. Epub 2019 Mar 5.

PMID:
30838773
5.

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.

6.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

7.

Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP.

J Hematol Oncol. 2018 Feb 20;11(1):23. doi: 10.1186/s13045-018-0561-0.

8.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

9.

BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5.

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH.

PLoS One. 2017 May 10;12(5):e0177188. doi: 10.1371/journal.pone.0177188. eCollection 2017.

10.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

11.

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.

PMID:
27341313
12.

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.

Exp Hematol. 2015 May;43(5):352-363.e4. doi: 10.1016/j.exphem.2015.01.008. Epub 2015 Jan 29.

13.

Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma.

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H.

Histopathology. 2015 Jul;67(1):62-9. doi: 10.1111/his.12624. Epub 2015 Feb 5.

PMID:
25431344
14.

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2015 Jun;56(6):1742-9. doi: 10.3109/10428194.2014.970550. Epub 2014 Nov 19.

PMID:
25284491
15.

Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.

Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, Gascoyne RD, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Vaidehi N, Staudt LM, Cyster JG.

Nature. 2014 Dec 11;516(7530):254-8. doi: 10.1038/nature13765. Epub 2014 Sep 28.

16.

A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.

Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB.

PLoS One. 2014 Sep 16;9(9):e104249. doi: 10.1371/journal.pone.0104249. eCollection 2014.

17.

Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.

Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A, Pedersen KW.

Clin Ther. 2014 Jun 1;36(6):847-862.e1. doi: 10.1016/j.clinthera.2014.05.010.

18.

Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, Staudt LM.

Cancer Discov. 2014 Apr;4(4):480-93. doi: 10.1158/2159-8290.CD-13-0915. Epub 2014 Feb 3.

19.

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H.

Leuk Lymphoma. 2014 Oct;55(10):2319-27. doi: 10.3109/10428194.2013.871632. Epub 2014 Mar 19.

PMID:
24432894
20.

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM.

Blood. 2014 Feb 20;123(8):1214-7. doi: 10.1182/blood-2013-11-536433. Epub 2014 Jan 7.

21.

Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma.

Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE.

Epigenetics. 2014 Mar;9(3):428-36. doi: 10.4161/epi.27554. Epub 2013 Dec 20.

22.

Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB.

Blood. 2014 Feb 13;123(7):1051-4. doi: 10.1182/blood-2013-07-512392. Epub 2013 Dec 19.

PMID:
24357726
23.

Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.

Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE.

PLoS One. 2013 Nov 19;8(11):e79602. doi: 10.1371/journal.pone.0079602. eCollection 2013.

24.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J.

Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

25.

Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome.

Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H.

Eur J Haematol. 2013 Oct;91(4):332-8. doi: 10.1111/ejh.12171. Epub 2013 Aug 17.

PMID:
23859481
26.

Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E.

Leuk Lymphoma. 2014 Feb;55(2):288-95. doi: 10.3109/10428194.2013.802778. Epub 2013 Jun 14.

PMID:
23662992
27.

Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2013 Oct;54(10):2205-14. doi: 10.3109/10428194.2013.774392. Epub 2013 Apr 2.

PMID:
23391141
28.

Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma.

Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH.

PLoS One. 2012;7(10):e46117. doi: 10.1371/journal.pone.0046117. Epub 2012 Oct 1.

29.

Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling.

Oksvold MP, Pedersen NM, Forfang L, Smeland EB.

FEBS Lett. 2012 Oct 19;586(20):3575-81. doi: 10.1016/j.febslet.2012.08.022. Epub 2012 Sep 6.

30.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.

Nature. 2012 Oct 4;490(7418):116-20. doi: 10.1038/nature11378. Epub 2012 Aug 12.

31.

SARA is dispensable for functional TGF-β signaling.

Bakkebø M, Huse K, Hilden VI, Forfang L, Myklebust JH, Smeland EB, Oksvold MP.

FEBS Lett. 2012 Sep 21;586(19):3367-72. doi: 10.1016/j.febslet.2012.07.027. Epub 2012 Jul 20.

32.

Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma.

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2012 Oct;53(10):1934-44. doi: 10.3109/10428194.2012.682307. Epub 2012 May 22.

PMID:
22475179
33.

Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times.

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B.

Br J Haematol. 2012 Jan;156(2):225-33. doi: 10.1111/j.1365-2141.2011.08942.x. Epub 2011 Nov 30.

PMID:
22126847
34.

Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7.

Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, Stokke T, Smeland EB, Myklebust JH.

Eur J Immunol. 2011 Nov;41(11):3135-45. doi: 10.1002/eji.201141558. Epub 2011 Oct 18.

35.

Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy.

Josefsen D, Forfang L, Dyrhaug M, Blystad AK, Stokke T, Smeland EB, Kvalheim G.

Eur J Haematol. 2011 Dec;87(6):494-502. doi: 10.1111/j.1600-0609.2011.01681.x. Epub 2011 Sep 15.

PMID:
21752097
36.

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.

Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-Palanco V, Prosper F, Lossos IS, Martinez-Climent JA.

Haematologica. 2011 Jul;96(7):980-6. doi: 10.3324/haematol.2011.040568. Epub 2011 Apr 1.

37.

Oncogenically active MYD88 mutations in human lymphoma.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.

Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

38.

Cooperative epigenetic modulation by cancer amplicon genes.

Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM.

Cancer Cell. 2010 Dec 14;18(6):590-605. doi: 10.1016/j.ccr.2010.11.013.

39.

TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK.

Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP.

BMC Immunol. 2010 Nov 23;11:57. doi: 10.1186/1471-2172-11-57.

40.

Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones.

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J.

Blood. 2010 Sep 2;116(9):1489-97. doi: 10.1182/blood-2010-03-272278. Epub 2010 May 26.

PMID:
20505157
41.

[Leadership and academic competence].

Smeland EB, Vartdal F, Wisløff F.

Tidsskr Nor Laegeforen. 2010 Mar 25;130(6):591. doi: 10.4045/tidsskr.10.0217. Norwegian. No abstract available.

42.

[Close cooperation, but not oversteering].

Smeland EB, Vartdal F, Wisløff F.

Tidsskr Nor Laegeforen. 2010 Mar 25;130(6):590-1. doi: 10.4045/tidsskr.10.0153. Norwegian. No abstract available.

43.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.

Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.

44.

[Molecular diagnosis of malignant lymphomas].

Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB.

Tidsskr Nor Laegeforen. 2009 Nov 19;129(22):2352-6. doi: 10.4045/tidsskr.09.0704. Review. Norwegian.

45.

Array-based DNA methylation profiling in follicular lymphoma.

O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J.

Leukemia. 2009 Oct;23(10):1858-66. doi: 10.1038/leu.2009.114. Epub 2009 Jul 9.

46.

Stromal gene signatures in large-B-cell lymphomas.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.

47.

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. doi: 10.1073/pnas.0804295105. Epub 2008 Sep 2.

48.

The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.

O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J.

Blood. 2008 Oct 15;112(8):3126-9. doi: 10.1182/blood-2008-05-154013. Epub 2008 Jul 15.

49.

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM.

Science. 2008 Mar 21;319(5870):1676-9. doi: 10.1126/science.1153629. Epub 2008 Mar 6.

50.

Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells.

Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH.

Eur J Immunol. 2007 Oct;37(10):2937-48.

Supplemental Content

Loading ...
Support Center